Akinc A, Maier MA, Manoharan M, et al. 2019 The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat. Nanotechnol. 14 1084–1087
Article ADS CAS PubMed Google Scholar
Al Hafid N and Christodoulou J 2015 Phenylketonuria: a review of current and future treatments. Transl. Pediatr. 4 304–317
PubMed PubMed Central Google Scholar
Alton EWFW AD, Ashby D, et al. on behalf of the UK Cystic Fibrosis Gene Therapy Consortium 2016 A randomised, double-blind, placebo-controlled trial of repeated nebulisation of non-viral cystic fibrosis transmembrane conductance regulator (CFTR) gene therapy in patients with cystic fibrosis (https://www.ncbi.nlm.nih.gov/books/NBK373648/)
An D, Schneller JL, Frassetto A, et al. 2017 Systemic messenger RNA therapy as a treatment for methylmalonic acidemia. Cell Rep. 21 3548–3558
Article CAS PubMed PubMed Central Google Scholar
An D, Frassetto A, Jacquinet E, Eybye M, et al. 2019 Long-term efficacy and safety of mRNA therapy in two murine models of methylmalonic acidemia. eBioMedicine 45 519–528
Anderson BR, Muramatsu H, Nallagatla SR, et al. 2010 Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation. Nucleic Acids Res. 38 5884–5892
Article CAS PubMed PubMed Central Google Scholar
Anderson EJ, Creech CB, Berthaud V, et al. 2022 Evaluation of mRNA-1273 vaccine in children 6 months to 5 years of age. N. Engl. J. Med. 387 1673–1687
Article CAS PubMed Google Scholar
Antoniou P, Miccio A and Brusson M 2021 Base and prime editing technologies for blood disorders. Front. Genome Ed. 3
Asrani KH, Farelli JD, Stahley MR, et al. 2018 Optimization of mRNA untranslated regions for improved expression of therapeutic mRNA. RNA Biol. 15 756–762
PubMed PubMed Central Google Scholar
August A, Attarwala HZ, Himansu S, et al. 2021 A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus. Nat. Med. 27 2224–2233
Article CAS PubMed PubMed Central Google Scholar
Baden LR, El Sahly HM, Essink B, et al. 2021 Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384 403–416
Article CAS PubMed Google Scholar
Bailey AL and Cullis PR 1994 Modulation of membrane fusion by asymmetric transbilayer distributions of amino lipids. Biochemistry 33 12573–12580
Article CAS PubMed Google Scholar
Baker RE and Shiman R 1979 Measurement of phenylalanine hydroxylase turnover in cultured hepatoma cells. J. Biol. Chem. 254 9633–9639
Article CAS PubMed Google Scholar
Baruteau J, Cunningham SC, Yilmaz BS, et al. 2021 Safety and efficacy of an engineered hepatotropic AAV gene therapy for ornithine transcarbamylase deficiency in cynomolgus monkeys. Mol. Ther. Methods. Clin. Dev. 23 135–146
Article CAS PubMed PubMed Central Google Scholar
Bavli Y, Chen B-M, Gross G, et al. 2023 Anti-PEG antibodies before and after a first dose of Comirnaty® (mRNA-LNP-based SARS-CoV-2 vaccine). J. Control. Release 354 316–322
Article CAS PubMed PubMed Central Google Scholar
Benenato K, Kumarasinghe ES and Cornebise M 2017 Compounds and compositions for intracellular delivery of therapeutic agents. US patent US20170210697
Bhandari JTP and Yadav D 2022 Crigler-Najjar syndrome (StatPearls Publishing) (https://www.ncbi.nlm.nih.gov/books/NBK562171/)
Bhat B, Karve S and Anderson DG 2021 mRNA therapeutics: beyond vaccine applications. Trends Mol. Med. 27 923–924
Article CAS PubMed Google Scholar
Bin Sawad A, Jackimiec J, Bechter M, et al. 2022 Epidemiology, methods of diagnosis, and clinical management of patients with arginase 1 deficiency (ARG1-D): A systematic review. Mol. Genet. Metab. 137 153–163
Article CAS PubMed Google Scholar
Blankenship CS 2008 To manage costs of hemophilia, patients need more than clotting factor. Biotechnol. Healthc. 5 37–40
PubMed PubMed Central Google Scholar
Blankenship K 2019 Alnylam wins FDA nod for $575,000 liver med Givlaari despite safety flags (https://www.fiercepharma.com/pharma/alnylam-scores-fda-approval-for-rare-liver-disease-med-givlaari)
Büning H 2013 Gene therapy enters the pharma market: the short story of a long journey. EMBO Mol. Med. 5 1–3
Article PubMed PubMed Central Google Scholar
Burke T, Asghar S, O’Hara J, et al. 2021 Clinical, humanistic, and economic burden of severe hemophilia B in the United States: Results from the CHESS US and CHESS US+ population surveys. Orphanet J. Rare Dis. 16 143
Article PubMed PubMed Central Google Scholar
Cacicedo ML, Weinl-Tenbruck C, Frank D, et al. 2022a Phenylalanine hydroxylase mRNA rescues the phenylketonuria phenotype in mice. Front. Bioeng. Biotechnol. 10 993298
Article PubMed PubMed Central Google Scholar
Cacicedo ML, Weinl-Tenbruck C, Frank D, et al. 2022b mRNA-based therapy proves superior to the standard of care for treating hereditary tyrosinemia 1 in a mouse model. Mol. Ther. Methods. Clin. Dev. 26 294–308
Article CAS PubMed PubMed Central Google Scholar
Cao J, An D, Galduroz M, et al. 2019 mRNA therapy improves metabolic and behavioral abnormalities in a murine model of citrin deficiency. Mol. Ther. 27 1242–1251
Article CAS PubMed PubMed Central Google Scholar
Cao J, Novoa EM, Zhang Z, et al. 2021a High-throughput 5′ UTR engineering for enhanced protein production in non-viral gene therapies. Nat. Commun. 12 4138
Article ADS CAS PubMed PubMed Central Google Scholar
Cao J, Choi M, Guadagnin E, et al. 2021b mRNA therapy restores euglycemia and prevents liver tumors in murine model of glycogen storage disease. Nat. Commun. 12 3090
Article ADS CAS PubMed PubMed Central Google Scholar
Chander N, Basha G, Yan Cheng MH, et al. 2023 Lipid nanoparticle mRNA systems containing high levels of sphingomyelin engender higher protein expression in hepatic and extra-hepatic tissues. Mol. Ther. Methods Clin. Dev. 30 235–245
Article CAS PubMed PubMed Central Google Scholar
Chavin SI 1984 Factor VIII: structure and function in blood clotting. Am. J. Hematol. 16 297–306
Article CAS PubMed Google Scholar
Chen C-Y, Tran DM, Cavedon A, et al. 2020 Treatment of hemophilia A using factor VIII messenger RNA lipid nanoparticles. Mol. Ther. Nucleic Acids 20 534–544
Article CAS PubMed PubMed Central Google Scholar
Chen R, Wang SK, Belk JA, et al. 2023a Engineering circular RNA for enhanced protein production. Nat. Biotechnol. 41 262–272
Article CAS PubMed Google Scholar
Chen T, Gao Y, Zhang S, et al. 2023b Methylmalonic acidemia: Neurodevelopment and neuroimaging. Front. Neurosci. 17 1110942
Article PubMed PubMed Central Google Scholar
Cheng Q, Wei T, Jia Y, et al. 2018 Dendrimer-based lipid nanoparticles deliver therapeutic FAH mRNA to normalize liver function and extend survival in a mouse model of hepatorenal tyrosinemia type I. Adv. Mater. 30 e1805308
Cheng Q, Wei T, Farbiak L, et al. 2020 Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat. Nanotechnol. 15 313–320
Article ADS CAS PubMed PubMed Central Google Scholar
Chou JY and Mansfield BC 2008 Mutations in the glucose-6-phosphatase-alpha (G6PC) gene that cause type Ia glycogen storage disease. Hum. Mutat. 29 921–930
Article CAS PubMed PubMed Central Google Scholar
Connolly B, Isaacs C, Cheng L, et al. 2018 SERPINA1 mRNA as a treatment for Alpha-1 antitrypsin deficiency. J. Nucleic Acids 2018 8247935
Article PubMed PubMed Central Google Scholar
Corbett KS, Edwards DK, Leist SR, et al. 2020 SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 586 567–571
Article ADS CAS PubMed PubMed Central Google Scholar
Cui T, Li B and Li W 2022 NTLA-2001: opening a new era for gene therapy. Life Med. 1 49–51
Da Silva Sanchez A, Paunovska K, Cristian A, et al. 2020 Treating cystic fibrosis with mRNA and CRISPR. Hum. Gene. Ther. 31 940–955
Article PubMed PubMed Central Google Scholar
Dass CR 2004 Lipoplex-mediated delivery of nucleic acids: factors affecting in
Comments (0)